Navigation Links
Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
Date:8/1/2008

NEW BRUNSWICK, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that Bayer CropScience has successfully completed the first R&D milestone related to Bayer's use of Senesco's technology in Brassica oilseeds.

Senesco's proprietary gene technology was licensed to Bayer CropScience in November 2006 to enhance Canola yields in Bayer's InVigor(R) canola hybrids and future hybrid's business internationally. Upon completion of this milestone, Senesco received an undisclosed payment from Bayer.

"We are pleased to arrive at this initial R&D milestone with Bayer CropScience," said Bruce Galton, President and CEO of Senesco. "We believe that our gene technology has broad application to both food and non-food crops."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
2. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
3. Senesco Technologies to Present at BIO 2008 Business Forum
4. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
5. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
6. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
8. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
9. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
10. Local officials move toward monitoring nanotechnologies
11. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   Intrexon Corporation ... first quarter 2015 financial results after the market closes ... conference call that day at 5:30 PM ET to ... The conference call may be accessed by ... to join the "Intrexon Conference Call."  Participants may also ...
(Date:5/1/2015)... OncoTAb, Inc., a University of North ... Pinku Mukherjee, Ph.D. has received the O. Max ... faculty honor. Mukherjee received the award, which recognizes ... research and development of cancer diagnostics and treatments. , ... in my scientific career,” said Mukherjee, OncoTAb Co-founder and ...
(Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... ) announced today that Roger Jeffs , Ph.D., President ... overview and update on the company,s business at the Deutsche ... Boston, Massachusetts . The presentation will ... Eastern Time, and can be accessed via a live webcast ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... DIEGO, March 28, 2012 OncoSec Medical Incorporated ... Medical System (OMS) ElectroOncology therapies to treat solid tumor ... institutional investors of an aggregate of 31,000,000 shares of ... registered public offering.  Additionally, investors received Warrants to purchase ...
... 2012 Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the ... financial results for the year ended December 31, 2011. ... December 31, 2011 were $7.7 million as compared to ... revenues was a result of a $5.0 million non-refundable ...
... computer chips are in demand. RUB physicists have discovered ... Dr. Padma Kant Shukla and Dr. Bengt Eliasson found ... charged potential makes it possible to combine positively charged ... this way, current can be conducted much more quickly ...
Cached Biology Technology:OncoSec Closes $7.75 Million Public Offering 2OncoSec Closes $7.75 Million Public Offering 3Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 2Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 3Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 4Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 5Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 6Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments 7When ions get closer 2
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... risk of anthrax infection in the Oct. 2001 attack on ... is published in the January 15 issue of The Journal ... the study shows, prompt intervention with antibiotics and vaccination appeared ... of 2001, a letter containing spores of Bacillus anthracis, the ...
... Ongoing global climate change causes changes in the species ... This applies also to fish populations. Previous studies demonstrating ... were based entirely on statistical data. However, in order ... a deeper understanding of the effect of water temperature ...
... by detecting the electrical equivalent of a living cell’s ... to both seeing the ‘heartbeat?of a living cell and ... stay alive, individual biological cells must transfer electrically charged ... produces an electrical current that could, in principle, be ...
Cached Biology News:Anthrax attack posed greater potential threat than thought 2How fish species suffer as a result of warmer waters 2A new study of living cells could revolutionize the way we test drugs 2